Skip to main content

CTT Pharmaceutical Holdings, Inc.

CTTH
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001035422

In the last 90 days, CTT Pharmaceutical Holdings, Inc. insiders filed 14 open-market purchases and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 12:11 PM ET

Income statement

Each column is one fiscal year, newest first.

Income statement of CTT Pharmaceutical Holdings, Inc., annual
Line itemFY2014FY2013FY2012FY2011
Period endDec 31, 2014Dec 31, 2013Dec 31, 2012Dec 31, 2011
Filing10-K/A10-K10-K10-K
Reported––––
Operating expenses$672.2K-$92.2K$1.19M$757.9K
Selling, general and administrative$17.6K-$160.4K$158.4K$316.4K
Operating income-$672.2K$92.2K-$1.19M-$757.9K
Net income-$672.2K$110.5K-$1.00M$3.74M
EPS, basic–$0.01$-0.11$0.42
EPS, diluted–$0.01$-0.11$0.40
Weighted shares, basic–9.41M9.41M8.92M
Weighted shares, diluted–9.41M9.41M9.49M
Margins and growth
Net income growth, year over year−708.5%–−126.8%–

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of CTT Pharmaceutical Holdings, Inc., annual
Line itemFY2014FY2013FY2012FY2011
Period endDec 31, 2014Dec 31, 2013Dec 31, 2012Dec 31, 2011
Filing10-K/A10-K10-K10-K
Reported––––
Cash and equivalents$81.2K$823$12.1K$569.4K
Short-term investments–$0$164.3K–
Accounts receivable$5.43K$5.43K$8.72K$151
Total current assets$1.05M$6.25K$203.1K$750.7K
Property, plant and equipment–––$0
Total assets$1.66M$6.25K$203.1K$4.18M
Total current liabilities–$249.4K$589.4K$3.73M
Total liabilities$169.5K$249.4K$589.4K$3.73M
Shareholders' equity$1.49M-$243.1K-$386.3K$456.4K

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of CTT Pharmaceutical Holdings, Inc., annual
Line itemFY2014FY2013FY2012FY2011
Period endDec 31, 2014Dec 31, 2013Dec 31, 2012Dec 31, 2011
Filing10-K/A10-K10-K10-K
Reported––––
Operating cash flow-$72.3K-$136.2K-$1.03M-$316.1K
Depreciation and amortization–––$0
Stock-based compensation$308.4K$0$42.3K$155.4K
Investing cash flow$151.9K$125.0K$436.0K$877.0K
Financing cash flow–$0$33.8K-$37.7K
Net change in cash$81.2K-$11.3K-$557.3K$523.2K

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for CTT Pharmaceutical Holdings, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Sep 11, 202659.7M–SEC
Nov 15, 201521.3M−88.4%SEC
Nov 10, 201521.3M−88.4%SEC
Nov 4, 201521.3M−88.4%SEC
Sep 30, 201521.3M−88.4%SEC
Aug 14, 2015195.1M+454.4%SEC
May 15, 2015195.1M+1,974.9%SEC
Apr 6, 2015195.1M+1,974.9%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.